Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

Corinne Faivre-Finn; Michael Snee; Linda Ashcroft; Wiebke Appel; Fabrice Barlesi; Adityanarayan Bhatnagar; Andrea Bezjak; Felipe Cardenal; Pierre Fournel; Susan Harden; Cecile Le Pechoux; Rhona McMenemin; Nazia Mohammed; Mary O'Brien; Jason Pantarotto; Veerle Surmont; Jan P Van Meerbeeck; Penella J Woll; Paul Lorigan; Fiona Blackhall

doi:10.1016/s1470-2045(17)30318-2

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30318-2 ◽

2017 ◽

Vol 18 (8) ◽

pp. 1116-1125 ◽

Cited By ~ 144

Author(s):

Corinne Faivre-Finn ◽

Michael Snee ◽

Linda Ashcroft ◽

Wiebke Appel ◽

Fabrice Barlesi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Once Daily ◽

Open Label Phase ◽

Superiority Trial

Download Full-text

Faculty Opinions recommendation of Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727730699.793574028 ◽

2020 ◽

Author(s):

Lorenzo Livi ◽

Isacco Desideri

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Once Daily ◽

Open Label Phase ◽

Superiority Trial

Download Full-text

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30641-0 ◽

2021 ◽

Vol 22 (2) ◽

pp. 198-211 ◽

Cited By ~ 2

Author(s):

Luis Paz-Ares ◽

Tudor-Eliade Ciuleanu ◽

Manuel Cobo ◽

Michael Schenker ◽

Bogdan Zurawski ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(21)00134-x ◽

2021 ◽

Author(s):

Jianxing He ◽

Chunxia Su ◽

Wenhua Liang ◽

Shidong Xu ◽

Lin Wu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Adjuvant Treatment ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Egfr Mutant

Download Full-text

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30339-x ◽

2017 ◽

Vol 18 (7) ◽

pp. 874-886 ◽

Cited By ~ 216

Author(s):

Alice T Shaw ◽

Tae Min Kim ◽

Lucio Crinò ◽

Cesare Gridelli ◽

Katsuyuki Kiura ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text

Abstract CT041: ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC)

10.1158/1538-7445.am2021-ct041 ◽

2021 ◽

Author(s):

Yuankai Shi ◽

Lin Wu ◽

Xinmin Yu ◽

Yan Wang ◽

Puyuan Xing ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated

Download Full-text

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(21)02098-5 ◽

2021 ◽

Author(s):

Enriqueta Felip ◽

Nasser Altorki ◽

Caicun Zhou ◽

Tibor Csőszi ◽

Ihor Vynnychenko ◽

...

Keyword(s):

Lung Cancer ◽

Adjuvant Chemotherapy ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Resected Stage

Download Full-text

Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial

The Lancet Healthy Longevity ◽

10.1016/s2666-7568(21)00255-5 ◽

2021 ◽

Vol 2 (12) ◽

pp. e791-e800 ◽

Cited By ~ 1

Author(s):

Yoshihito Kogure ◽

Shunichiro Iwasawa ◽

Hideo Saka ◽

Yoichiro Hamamoto ◽

Akiko Kada ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Older Patients ◽

Small Cell ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdx091.064 ◽

2017 ◽

Vol 28 ◽

pp. ii50-ii51 ◽

Cited By ~ 4

Author(s):

L. Paz-Ares ◽

J. Brahmer ◽

M.D. Hellmann ◽

M. Reck ◽

K. O'Byrne ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

481TiP Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ non-small cell lung cancer (NSCLC): Randomized, open-label, phase 3 KEYNOTE-042 study

Annals of Oncology ◽

10.1093/annonc/mdv532.65 ◽

2015 ◽

Vol 26 ◽

pp. ix125

Author(s):

T. Mok ◽

Y.-L. Wu ◽

S. Sadowski ◽

J. Zhang ◽

R. Rangwala ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Platinum Based Chemotherapy ◽

Open Label Phase

Download Full-text

Post-Operative Radiotherapy (PORT) Versus No PORT in Patients With Completely Resected Non-Small Cell Lung Cancer and Proven Mediastinal N2 Involvement: An Open Label Randomised Phase 3 Superiority Trial (Lung ART (IFCT-0503, UK NCRI, SAKK))

SSRN Electronic Journal ◽

10.2139/ssrn.3875389 ◽

2021 ◽

Author(s):

Cecile Le Pechoux ◽

Nicolas Pourel ◽

Fabrice Barlesi ◽

Delphine Lerouge ◽

Delphine Antoni ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Superiority Trial

Download Full-text